Improved Hemoglobin A1c (HbA1c) and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS
Primary result · Change from baseline in HbA1cResult — go to the resultEstimated difference 0.21 % 95% CI 0.03–0.39Authors' conclusion
In this post hoc analysis, tirzepatide was associated with substantial reductions in HbA1c and BW irrespective of GADA status in adults diagnosed with T2D, suggesting that tirzepatide may improve glycemic control in individuals with LADA.
Study context
- Population
- Adults with clinically diagnosed T2D treated with tirzepatide (5, 10, 15 mg) in SURPASS 2–5, with confirmed GADA statuspooled SURPASS 2–5
- Participants
- 3,791 adults
- Comparison
- GADA-positive vs GADA-negative participants treated with tirzepatide
- GADA positiven = 120
- GADA negativen = 3,671reference
- Primary endpoint
- Change from baseline in HbA1c by GADA status
- Follow-up
- Weeks 40 (SURPASS-2, −3, −5) and 42 (SURPASS-4)
Methodological detailspooled data, mixed-model repeated measures, efficacy analysis set, adjusted for study and baseline covariates
- Pooled data
- Mixed-model repeated measures
- Efficacy analysis set
- Adjusted for study and baseline covariates
Primary result
Change from baseline in HbA1c · week 40/42
Estimated difference
0.21 %
95% CI 0.03–0.39
P = 0.024
Change by group
GADA-positive
−2.11
%
GADA-negative
−2.32
%
GADA-positivevs GADA-negative
estimated difference 0.21 % (95% CI 0.03–0.39); P = 0.024
As reported in the abstract
- Within-group HbA1c reductions significant in both groups
- P < 0.001
Further findings
kg
| Outcome | GADA positive | GADA negative | Estimated difference (kg) (95% CI) | P value | |
|---|---|---|---|---|---|
| Change from baseline in body weight · week 40/42Did not differ between groups | −9.2 | −9.6 | 0.38 (−0.99 to 1.75) | P = 0.588 | |
| −1012Difference, kg (linear scale) |
Mean
| Outcome | GADA positive | GADA negative |
|---|---|---|
| Baseline BMI | 32.2 (SD 6.1) | 33.6 (SD 6.3) |
- Change from baseline in body weight — Within-group body weight (BW) reductions significant in both groups
- P < .001
Baseline body mass index (BMI)
- Other baseline characteristics similar between groups
Original publication
Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS. J Clin Endocrinol Metab. Published 3 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →